Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Asset Writedowns and Impairment (2018 - 2025)

Historic Asset Writedowns and Impairment for Integra Lifesciences Holdings (IART) over the last 7 years, with Q2 2025 value amounting to $511.4 million.

  • Integra Lifesciences Holdings' Asset Writedowns and Impairment rose 996624.02% to $511.4 million in Q2 2025 from the same period last year, while for Sep 2025 it was $511.4 million, marking a year-over-year increase of 410110.9%. This contributed to the annual value of $12.2 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q2 2025, Integra Lifesciences Holdings' Asset Writedowns and Impairment is $511.4 million, which was up 996624.02% from $36000.0 recorded in Q4 2024.
  • Integra Lifesciences Holdings' 5-year Asset Writedowns and Impairment high stood at $511.4 million for Q2 2025, and its period low was $29000.0 during Q3 2024.
  • Over the past 3 years, Integra Lifesciences Holdings' median Asset Writedowns and Impairment value was $3.9 million (recorded in 2021), while the average stood at $87.7 million.
  • Over the last 5 years, Integra Lifesciences Holdings' Asset Writedowns and Impairment had its largest YoY gain of 996624.02% in 2025, and its largest YoY loss of 996624.02% in 2025.
  • Integra Lifesciences Holdings' Asset Writedowns and Impairment (Quarter) stood at $2.8 million in 2021, then plummeted by 98.69% to $36000.0 in 2024, then surged by 1420358.33% to $511.4 million in 2025.
  • Its Asset Writedowns and Impairment was $511.4 million in Q2 2025, compared to $36000.0 in Q4 2024 and $29000.0 in Q3 2024.